Business
Jupiter Neurosciences Addresses Market Volatility as it Remains Focused on Advancing Clinical and Commercial Milestones
Jupiter, Florida, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical
About this update from Jupiter Neurosciences, Inc.
[{"type":"text","content":"Jupiter, Florida, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, today issued a statement regarding recent market volatility and highlighted its planned Direct-to-Consumer product launch later this year, which is expected to generate near-term revenues while the Company advances its clinical trials. “The recent volatility in our stock appears to be driven by misconceptions and a lack of understanding about our business and long-term strategy, but I want to reassure our investors that there have been no undisclosed material developments,” said Christer Rosén, Chairman and CEO of Jupiter Neurosciences. “Our recent announcements, including partnerships with Zina Biopharmaceuticals and Catalent Pharma Solutions, are important milestones in advancing JOTROL™ for our planned Phase 2a study in Parkinson’s disease. With these partnerships in place, we are making tangible progress in our clinical development and remain confident in the path ahead.” Jupiter is advancing a robust clinical pipeline addressing combined market opportunities exceeding $50 billion. The Company is focused on significant unmet needs in CNS disorders, including Alzheimer’s, Parkinson’s, and rare diseases such as MPS-I, Friedreich’s Ataxia, and MELAS. With multiple Phase 2 trials scheduled to launch within the next 12 months—leveraging successful Phase 1 data demonstrating safety—Jupiter is well-positioned for meaningful clinical advancements. In addition to its clinical pipeline development, Jupiter is poised to generate near-term revenue with the upcoming launch of its direct-to-consumer product line in 2025. This initiative represents a key step in diversifying the Company’s business model, providing immediate cash flow while continuing to advance its pharmaceutical pipeline. Focused on the longevity and aging market, the Company expects to share more details soon about two initial products leveraging the unique bioavailability and therapeutic advantages of JOTROL™, which has demonstrated significantly enhanced bioavailability compared to traditional resveratrol formulations. Rosén also commented on the Company’s financial strategy: “While we remain open to strategic funding opportunities, we are committed...